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Virology SelectViruses are the scourge of mankind, causing devastating pandemics such as the 1918 Spanish flu and AIDS. This Virology
Select highlights new studies that shed light on how viruses invade host cells so efficiently and how they evade the host
immune response by stowing away in immune cells or by constantly changing their surface armor.HA (grey) of the H1N1 flu virus from pandemic
(left) and seasonal (right) strains, with sites
for antibody binding (red) and glycosylation
(blue). Image courtesy of J. Boyington and
G. Nabel.The Ghost of Spanish Flu Past
The opening decade of the 21st century witnessed the first flu pandemic in
40 years. Eerily enough, the culprit, an H1N1 influenza virus of swine origin,
turns out to have important similarities to the H1N1 strain that caused the cata-
strophic 1918 Spanish flu, as two new studies now report (Wei et al., 2010;
Xu et al., 2010). One of the most puzzling aspects of the 2009 H1N1 flu
pandemic was that children and young adults were far more susceptible
than individuals aged 65 or over (usually the population most at risk during
seasonal flu outbreaks), suggesting that older individuals had some immunity.
But flu viruses are known to evolve rapidly to evade the host immune response,
and so it is unclear how older individuals could be partly immune to the 2009
H1N1 strain, given that almost a century separates it from the 1918 pandemic
flu virus. One way that flu viruses evade the host immune response is by
antigenic drift, which involves substitution of amino acids in a key surface
glycoprotein called hemagglutinin (HA). HA enables flu viruses to bind and
enter host cells and is a major target of antibodies produced by the host’s
immune system. Now, Wei et al. (2010) report the surprising result that the1918 and 2009 H1N1 pandemic flu viruses have a remarkable degree of antigenic cross-reactivity despite being separated
by almost a century. Mice injected with a DNA vaccine for the 1918 H1N1 virus produced antibodies that protected them
against challenge with the 2009 H1N1 virus, and vice versa. These cross-neutralizing antibodies did not protect mice against
infection with other circulating H1N1 viruses that cause seasonal flu. But which viral epitopes elicit these cross-neutralizing
antibodies? A big clue comes from Xu et al.’s elegant structural study of the HA from both the 1918 and 2009 H1N1 strains.
Using an antibody against the HA of the 1918 virus obtained from a patient who actually survived the Spanish flu, the inves-
tigators pinpointed an epitope in the HA head region of both viruses that bound the antibody. The epitope, close to the
receptor-binding region in the HA head, differed by only a couple of amino acids between the two pandemic virus strains
but showed remarkable divergence in other circulating H1N1 seasonal flu viruses.Antibody (red, yellow) from an
individual who survived the
1918 Spanish flu bound to theBut this is only part of the story. Both groups realized that the pattern of sugars (glycans)
attached to the HA head was very different in the pandemic and seasonal H1N1 viruses.
The HA head of the pandemic strains was devoid of glycans in the region where cross-
neutralizing antibodies bind, in contrast to the HA head of the seasonal strains that had
a glycan cap, which prevented antibody binding. When Wei et al. looked at a broad swath
of H1N1 strains they discovered that within two decades of 1918, the virus not only had
made a number of amino acid swaps in the main HA epitope but also had acquired glycans
that shielded this region from antibodies, thus altering the antigenicity of the virus and its
sensitivity to neutralization. But why doesn’t the new 2009 H1N1 virus have this glycan
cap? The authors propose that because this strain is of swine origin it is not under the
same selective pressure as the human H1N1 viruses and therefore its HA head has remained
glycan-free like that of the 1918 H1N1 virus. These findings hold important lessons for devel-
oping effective flu vaccines and for monitoring the trajectory of influenza virus evolution both
in humans and in the animal reservoirs from which the next flu pandemic strain is likely to
emerge.
C.-J. Wei et al. (2010). Science Trans. Med. 2, 24ra21.
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D. Ekiert.HIV: A Stem Cell Stowaway?
Altering their antigenic armor is only one mode of escape for viruses. In the case of HIV, this
wily retrovirus is able to hide out in certain blood cells where it is protected from the dual threats of the host immune system
and triple drug therapy (HAART). Resting CD4+ T lymphocytes are known to harbor this latent form of HIV. But when these
cells become activated, viral gene expression is switched on, the virus replicates, and the cells die resulting in severe
immunosuppression. Carter et al. (2010) now pinpoint another potential safe haven for latent HIV: the CD34+ hematopoietic
progenitor cells of human bone marrow. When they cultured these CD34+ cells with HIV, most of the cells became infected
and died within 7 days. However, in a subpopulation of infected CD34+ cells, viral genes were not expressed and the cells
did not die. CD34+ human bone marrow cells are heterogeneous comprising mostly multipotent hematopoietic progenitorCell 141, April 16, 2010 ª2010 Elsevier Inc. 197
cells with a small number of pluripotent stem cells. Seven days after initial infection, the cultured HIV-infected CD34+ cells
were treated with the growth factors GM-CSF and TNF-a and began to differentiate into myeloid cells like macrophages.
Differentiation activated latent HIV, which switched on expression of its viral genes and produced virions, which were able
to infect cultured T lymphocytes. The authors then engineered a latency reporter virus with which they were able to detect
HIV in some cultured CD34+ cells for as long as 20 days, suggesting that the virus is indeed latent. But are these findings
relevant in vivo? The authors obtainedCD34+ bonemarrow cells fromHIV-infected patients with high levels of circulating virus
(viral load) and found that after growth-factor treatment the virus could be found in all marrow samples. Next they looked at
CD34+ marrow cells from HIV-infected individuals on HAART therapy with no detectable viral load and found strong evidence
for latent HIV (integration of the viral genome with the CD34+ cell genome) in these patients. These findings have important
ramifications because if HIV inhabits CD34+ pluripotent stem cells that are long-lived and quiescent then it will be extremely
difficult to eradicate this virus. The next steps will be to prove that HIV does indeed infect the hematopoietic pluripotent stem
cell population and to pinpoint the host factors that influence reactivation of the latent virus.
C.C. Carter et al. (2010). Nat. Med. Published online March 7, 2010. 10.1038/nm.2109.A HIV-1 virion trapped at the host cell
surface by tetherin. Image courtesy of
W. Weissenhorn.Far away, So close
Viruses may have devised numerous ways to evade detection, but host cells have
their own set of tricks. Mammalian cells contain a variety of antiviral (restriction)
factors that interrupt the virus at different stages of the life cycle. For example, the
restriction factor tetherin prevents the release of enveloped viruses such as HIV-1
from the host cell surface. Tetherin comprises a small cytosolic domain, an N-
terminal transmembrane domain, and an extracellular domain attached to a second
membrane anchor. Analyzing a 2.77 A˚ crystal structure of the tetherin extracellular
domain, Hinz et al. (2010) now report characteristics of this molecule that make it
ideally suited to prevent the budding and escape of HIV-1. In particular, by mutating
residues in a 90 A˚-long disulfide-linked coiled-coil region of the extracellular domain,
they show that this coiled-coil region is essential for tetherin’s antiviral activity. The
authors surmise that the coiled-coil domain could act like a flexible spring as it hasa number of conserved destabilizing residues. They propose that the N-terminal domain of tetherin is anchored in the host
cell plasma membrane and the second membrane anchor is inserted into the virion’s envelope with the coiled-coil domain
stretching between them. The coiled-coil domain may act like a spring that can extend and retract, thus ensuring that the
captured virions can’t break free.
A. Hinz et al. (2010). Cell Host Microbe. Published online April 15, 2010. 10.1016/j.chom.2010.03.005.Speed Demons of the Virus World
Evading detection is just one part of the success story of viral pathogens. Certain viruses have also developed remarkable
ways to speed up their transmission from cell to cell. Such virus spread is thought to be dependent on the kinetics of virus
replication. But when Doceul et al. (2010) looked at cultured epithelial cells infected with the poxvirus vaccinia, they found
to their surprise that the rate of virus spread was 4-fold greater than would be predicted from the poxvirus replication rate.
They then discovered that the vaccinia virus has evolved an ingenious way to speed up transmission of its virions from cell
to cell and hence its infection rate. Using live-cell imaging, the authors observed that microvilli on the surface of infected
host cells seemed to be pushing virions in the direction of uninfected cells. But how could virions be actively involved in
this one-way tennis match? It turns out that when the virus first infects a host cell it induces production of two viral proteins,
A33 and A36, which become expressed on the host cell surface. Upon contact with additional virus particles trying to infect
the cell, A36 becomes phosphorylated resulting in activation of Arp2/3 (a major driver of actin polymerization) and the forma-
tion of actin tails in the host cell microvillus to which the virus particles are attached. This extendedmicrovillus then pushes the
virions away from the infected cell towards neighboring cells. If the next cell is also infected, the virus particles induce new
actin tails in the microvilli, which push the virions away once more. Finally, the virions come to rest on an uninfected cell
and infection ensues. This remarkable mechanism not only speeds up the spread of virus but also prevents superinfection
(reinfection of an infected cell), ensuring that every host cell becomes infected and thus maximizing the efficiency of infection.
The big question is whether other viruses also use a similar mechanism to boost their infection rates.
V. Doceul et al. (2010). Science 327, 873–876.
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